



## Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

Toshio Shimizu<sup>1</sup> · Yasutoshi Kuboki<sup>2</sup> · Chia-Chi Lin<sup>3</sup> · Kan Yonemori<sup>1</sup> · Tomoko Yanai<sup>4</sup> · Douglas V. Faller<sup>5</sup> · Iwona Dobler<sup>5</sup> · Neeraj Gupta<sup>5</sup> · Farhad Sedarati<sup>5</sup> · Kyu-pyo Kim<sup>6</sup>

Published online: 12 April 2022  
© The Author(s) 2022

**Correction to: Targeted Oncology (2022) 17:15–24**  
<https://doi.org/10.1007/s11523-021-00855-w>

The article "A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies", written by Toshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, Kan Yonemori, Tomoko Yanai, Douglas V. Faller, Iwona Dobler, Neeraj Gupta, Farhad Sedarati, Kyu-pyo Kim, was originally published Online First without Open Access. After publication in volume 17, issue 1, pages 15–24 the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2022 and the article is forthwith distributed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence,

unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article has been corrected.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s11523-021-00855-w>.

✉ Toshio Shimizu  
tosshimi@ncc.go.jp

- <sup>1</sup> Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
- <sup>2</sup> National Cancer Center Hospital East, Chiba, Japan
- <sup>3</sup> National Taiwan University Hospital, Taipei, Taiwan
- <sup>4</sup> Takeda Pharmaceutical Company Limited, Osaka, Japan
- <sup>5</sup> Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
- <sup>6</sup> Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea